The WACC of Chemesis International Inc (CSI.CN) is 7.5%.
Range | Selected | |
Cost of equity | 6.0% - 9.1% | 7.55% |
Tax rate | 0.1% - 0.3% | 0.2% |
Cost of debt | 4.0% - 7.0% | 5.5% |
WACC | 5.9% - 9.1% | 7.5% |
Category | Low | High |
Long-term bond rate | 3.6% | 4.1% |
Equity market risk premium | 5.5% | 6.5% |
Adjusted beta | 0.44 | 0.7 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 6.0% | 9.1% |
Tax rate | 0.1% | 0.3% |
Debt/Equity ratio | 0.02 | 0.02 |
Cost of debt | 4.0% | 7.0% |
After-tax WACC | 5.9% | 9.1% |
Selected WACC | 7.5% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
CSI.CN | Chemesis International Inc | 0.02 | 1.5 | 1.48 |
CPTR.CN | Captor Capital Corp | 5.82 | -8.52 | -1.25 |
EAT.CN | Nutritional High International Inc | 2.91 | 0.9 | 0.23 |
GRIN.CN | Grown Rogue International Inc | 0.09 | 1.72 | 1.57 |
HVT.V | Harvest One Cannabis Inc | 0.28 | 1.81 | 1.41 |
IPCI.TO | Intellipharmaceutics International Inc | 1.06 | -0.25 | -0.12 |
NRTH.V | 48North Cannabis Corp | 0.05 | 1.3 | 1.23 |
OILS.CN | Nextleaf Solutions Ltd | 0.04 | 1.96 | 1.89 |
TRGM | Targeted Medical Pharma Inc | 175378.94 | 0.7 | 0 |
VIV.V | Avivagen Inc | 15.67 | 6.27 | 0.38 |
Low | High | |
Unlevered beta | 0.32 | 1.31 |
Relevered beta | 0.16 | 0.55 |
Adjusted relevered beta | 0.44 | 0.7 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for CSI.CN:
cost_of_equity (7.55%) = risk_free_rate (3.85%) + equity_risk_premium (6.00%) * adjusted_beta (0.44) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.